De novo drug design is a pivotal issue in pharmacology and a new area of focus in AI for science research. A central challenge in this field is to generate molecules with specific properties while also producing a wide range of diverse candidates. Although advanced technologies such as transformer models and reinforcement learning have been applied in drug design, their potential has not been fully realized. Therefore, we propose MolRL-MGPT, a reinforcement learning algorithm with multiple GPT agents for drug molecular generation. To promote molecular diversity, we encourage the agents to collaborate in searching for desirable molecules in diverse directions. Our algorithm has shown promising results on the GuacaMol benchmark and exhibits efficacy in designing inhibitors against SARS-CoV-2 protein targets. The codes are available at: https://github.com/HXYfighter/

A central challenge in this field is to generate molecules with specific properties while also producing a wide range of diverse candidates. Although advanced technologies such as transformer models and reinforcement learning have been applied in drug design, their potential has not been fully realized. Therefore, we propose MolRL-MGPT, a reinforcement learning algorithm with multiple GPT agents for drug molecular generation. To promote molecular diversity, we encourage the agents to collaborate in searching for desirable molecules in diverse directions. Our algorithm has shown promising results on the GuacaMol benchmark and exhibits efficacy in designing inhibitors against SARS-CoV-2 protein targets.

In many real-world applications, evaluating the quality of instances is costly and time-consuming, e.g., human feedback and physics simulations, in contrast to proposing new instances. In particular, this is even more critical in reinforcement learning, since it relies on interactions with the environment (i.e., new instances) that must be evaluated to provide a reward signal for learning. At the same time, performing sufficient exploration is crucial in reinforcement learning to find high-rewarding solutions, meaning that the agent should observe and learn from a diverse set of experiences to find different solutions. Thus, we argue that learning from a diverse mini-batch of experiences can have a large impact on the exploration and help mitigate mode collapse. In this paper, we introduce mini-batch diversification for reinforcement learning and study this framework in the context of a real-world problem, namely, drug discovery. We extensively evaluate how our proposed framework can enhance the effectiveness of chemical exploration in de novo drug design, where finding diverse and high-quality solutions is crucial. Our experiments demonstrate that our proposed diverse mini-batch selection framework can substantially enhance the diversity of solutions while maintaining high-quality solutions. In drug discovery, such an outcome can potentially lead to fulfilling unmet medical needs faster.

Fine-tuning a pre-trained generative model has demonstrated good performance in generating promising drug molecules. The fine-tuning task is often formulated as a reinforcement learning problem, where previous methods efficiently learn to optimize a reward function to generate potential drug molecules. Nevertheless, in the absence of an adaptive update mechanism for the reward function, the optimization process can become stuck in local optima. The efficacy of the optimal molecule in a local optimization may not translate to usefulness in the subsequent drug optimization process or as a potential standalone clinical candidate. Therefore, it is important to generate a diverse set of promising molecules. Prior work has modified the reward function by penalizing structurally similar molecules, primarily focusing on finding molecules with higher rewards. To date, no study has comprehensively examined how different adaptive update mechanisms for the reward function influence the diversity of generated molecules. In this work, we investigate a wide range of intrinsic motivation methods and strategies to penalize the extrinsic reward, and how they affect the diversity of the set of generated molecules. Our experiments reveal that combining structure- and prediction-based methods generally yields better results in terms of molecular diversity.

De novo drug design is a pivotal issue in pharmacology and a new area of focus in AI for science research. A central challenge in this field is to generate molecules with specific properties while also producing a wide range of diverse candidates. Although advanced technologies such as transformer models and reinforcement learning have been applied in drug design, their potential has not been fully realized. Therefore, we propose MolRL-MGPT, a reinforcement learning algorithm with multiple GPT agents for drug molecular generation. To promote molecular diversity, we encourage the agents to collaborate in searching for desirable molecules in diverse directions.

Developing new drugs is laborious and costly, demanding extensive time investment. In this study, we introduce an innovative de-novo drug design strategy, which harnesses the capabilities of language models to devise targeted drugs for specific proteins. Employing a Reinforcement Learning (RL) framework utilizing Proximal Policy Optimization (PPO), we refine the model to acquire a policy for generating drugs tailored to protein targets. Our method integrates a composite reward function, combining considerations of drug-target interaction and molecular validity. Following RL fine-tuning, our approach demonstrates promising outcomes, yielding notable improvements in molecular validity, interaction efficacy, and critical chemical properties, achieving 65.37 for Quantitative Estimation of Drug-likeness (QED), 321.55 for Molecular Weight (MW), and 4.47 for Octanol-Water Partition Coefficient (logP), respectively. Furthermore, out of the generated drugs, only 0.041\% do not exhibit novelty.

De novo drug design is a pivotal issue in pharmacology and a new area of focus in AI for science research. A central challenge in this field is to generate molecules with specific properties while also producing a wide range of diverse candidates. Although advanced technologies such as transformer models and reinforcement learning have been applied in drug design, their potential has not been fully realized. Therefore, we propose MolRL-MGPT, a reinforcement learning algorithm with multiple GPT agents for drug molecular generation. To promote molecular diversity, we encourage the agents to collaborate in searching for desirable molecules in diverse directions. Our algorithm has shown promising results on the GuacaMol benchmark and exhibits efficacy in designing inhibitors against SARS-CoV-2 protein targets. The codes are available at: https://github.com/HXYfighter/

De novo drug design requires simultaneously generating novel molecules outside of training data and predicting their target properties, making it a hard task for generative models. To address this, we propose Joint Transformer that combines a Transformer decoder, Transformer encoder, and a predictor in a joint generative model with shared weights. We formulate a probabilistic black-box optimization algorithm that employs Joint Transformer to generate novel molecules with improved target properties and outperforms other SMILES-based optimization methods in de novo drug design.

In recent years, deep learning has demonstrated promising results in de novo drug design. However, the proposed techniques still lack an efficient exploration of the large chemical space. Most of these methods explore a small fragment of the chemical space of known drugs, if the desired molecules were not found, the process ends. In this work, we introduce a curiosity-driven method to force the model to navigate many parts of the chemical space, therefore, achieving higher desirability and diversity as well. At first, we train a recurrent neural network-based general molecular generator (G), then we fine-tune G to maximize curiosity and desirability. We define curiosity as the Tanimoto similarity between two generated molecules, a first molecule generated by G, and a second one generated by a copy of G (Gcopy). We only backpropagate the loss through G while keeping Gcopy unchanged. We benchmarked our approach against two desirable chemical properties related to drug-likeness and showed that the discovered chemical space can be significantly expanded, thus, discovering a higher number of desirable molecules with more diversity and potentially easier to synthesize. All Code and data used in this paper are available at https://github.com/amine179/Curiosity-RL-for-Drug-Design.